Patients in nearly half the country can't get appointments with specialist teams for weight-loss support and care, including treatment with drugs such as semaglutide. And in nearly one in five local health areas, patients don't have access to a bariatric surgery service, reports Elisabeth Mahase.
Obesity treatments being restricted by cash poor local services across England, investigation finds retrieved 11 September 2024 from https://medicalxpress.com/news/2024-09-obesity-treatments-restricted-cash-poor.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Feb 19, 2024Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide reduces risk for major adverse cardiovascular events in patients with obesity and heart failureSemaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points compared with placebo in patients with overweight or obesity and heart failure, according to a study published online Aug. 24 in The Lancet.
Read more »
Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patientsA study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.
Read more »
Semaglutide reduces COVID-19 related deaths in patients with obesity and cardiovascular diseaseSemaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease (CVD) without diabetes, according to a new study published in JACC.
Read more »
Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesitySemaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.
Read more »
Cancerous uterine tumors found to be more aggressive in Black patients than white patientsNorthwestern Medicine investigators have discovered that uterine serous carcinoma (USC) tumors in Black patients express more aggressive and immunosuppressive features than tumors in white patients, according to a new study published Aug. 12 in the Proceedings of the National Academy of Sciences.
Read more »
Report finds one-fifth of patients in areas of Northern England have suffered from long COVIDNew research led by Dr. Stephanie Scott found people in the North of England are among the worst affected by long COVID, which follows patterns highlighting the devastating impact of COVID-19 across northern regions in comparison to southern areas.
Read more »